Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2020-01-06 Regulatory Filings
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from Menlo Therapeutics, Inc. to the SEC requesting acceleration of the effectiveness of a Registration Statement on Form S-4. It references a specific SEC filing (Form S-4) and requests an effective date and time for the registration statement. The content is a formal request related to a regulatory filing process rather than the filing itself or a report containing financial data. The document length is short (1980 characters), and it is clearly a correspondence related to a regulatory filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2020-01-06 English
S-4/A
Merger & Acquisition Classification · 100% confidence The document is a Form S-4/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It relates to a merger transaction between Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd. The document includes detailed information about the merger proposal, share exchange ratios, meeting dates for shareholder votes, and other merger-related disclosures. Form S-4 filings are used for securities registration in connection with mergers and acquisitions. This is not a simple announcement or proxy solicitation but a comprehensive registration statement related to a merger transaction. Therefore, the appropriate classification is 'Merger & Acquisition' (MA). The document length and content confirm it is the filing itself, not just an announcement or proxy statement.
2020-01-06 English
425 Filing
Investor Presentation Classification · 100% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934, which are commonly used for merger communications. The text is an extensive investor presentation dated December 20, 2019, discussing a merger transaction between Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd. It includes detailed strategic rationale, transaction highlights, pipeline information, clinical trial results, and commercial opportunities. The content is clearly a detailed presentation aimed at investors about the merger and related business prospects. There is no indication that this is a full annual report, earnings release, or regulatory filing. The presence of detailed slides and forward-looking statements typical of investor presentations confirms this classification. Therefore, the document is best classified as an Investor Presentation (IP).
2019-12-20 English
FORM 4/A SUBMISSION
Director's Dealing
2019-12-16 English
FORM 4/A SUBMISSION
Director's Dealing
2019-12-16 English
FORM 4/A SUBMISSION
Director's Dealing
2019-12-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.